These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 31425489)

  • 1. Population Pharmacokinetics of Ganciclovir in Critically Ill Patients.
    Krens SD; Hodiamont CJ; Juffermans NP; Mathôt RAA; van Hest RM
    Ther Drug Monit; 2020 Apr; 42(2):295-301. PubMed ID: 31425489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Cockcroft-Gault, MDRD and CKD-EPI equations for estimating ganciclovir clearance.
    Palacio-Lacambra ME; Comas-Reixach I; Blanco-Grau A; Suñé-Negre JM; Segarra-Medrano A; Montoro-Ronsano JB
    Br J Clin Pharmacol; 2018 Sep; 84(9):2120-2128. PubMed ID: 29791023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Three Renal Function Formulas for Ganciclovir/Valganciclovir Dose Individualization in CMV-Infected Solid Organ Transplantation Patients Using a Population Approach.
    Lalagkas PN; Iliou J; Rigo R; Miarons M; Fernández-Alarcon B; Bestard O; Cruzado JM; Melilli E; Torras J; Grinyó JM; Lloberas N; Colom H
    Clin Pharmacokinet; 2023 Jun; 62(6):861-880. PubMed ID: 37140726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ganciclovir in pediatric renal transplant recipients.
    Zhang D; Lapeyraque AL; Popon M; Loirat C; Jacqz-Aigrain E
    Pediatr Nephrol; 2003 Sep; 18(9):943-8. PubMed ID: 12883977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics of Ganciclovir in Allogeneic Hematopoietic Stem Cell Transplant Patients.
    Selby PR; Heffernan AJ; Yeung D; Warner MS; Peake SL; Hahn U; Wallis SC; Mcwhinney B; Ungerer JPJ; Shakib S; Roberts JA
    Antimicrob Agents Chemother; 2023 Mar; 67(3):e0155022. PubMed ID: 36815858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics and Bayesian Estimation of the Area Under the Concentration-Time Curve for Ganciclovir in Adult Chinese Renal Allograft Recipients After Valganciclovir Administration.
    Chen B; Hu SS; Rui WB; An HM; Zhai XH; Wang XH; Lu JQ; Shao K; Zhou PJ
    J Clin Pharmacol; 2021 Mar; 61(3):328-338. PubMed ID: 32926418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis.
    De Winter S; van Hest R; Dreesen E; Annaert P; Wauters J; Meersseman W; Van den Eede N; Desmet S; Verelst S; Vanbrabant P; Peetermans W; Spriet I
    Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):653-663. PubMed ID: 34297338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
    Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J
    Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients.
    Franck B; Woillard JB; Théorêt Y; Bittencourt H; Demers E; Briand A; Marquet P; Lapeyraque AL; Ovetchkine P; Autmizguine J
    Br J Clin Pharmacol; 2021 Aug; 87(8):3105-3114. PubMed ID: 33373493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ganciclovir treatment in children: evidence of subtherapeutic levels.
    Luck S; Lovering A; Griffiths P; Sharland M
    Int J Antimicrob Agents; 2011 May; 37(5):445-8. PubMed ID: 21300526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients.
    Horvatits T; Kitzberger R; Drolz A; Zauner C; Jäger W; Böhmdorfer M; Kraff S; Fritsch A; Thalhammer F; Fuhrmann V; Schenk P
    Antimicrob Agents Chemother; 2014; 58(1):94-101. PubMed ID: 24145543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function.
    Pescovitz MD; Pruett TL; Gonwa T; Brook B; McGory R; Wicker K; Griffy K; Robinson CA; Jung D
    Transplantation; 1998 Oct; 66(8):1104-7. PubMed ID: 9808499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of anidulafungin in ICU patients assessing inter- and intrasubject variability.
    Kapralos I; Mainas E; Apostolopoulou O; Siopi M; Neroutsos E; Apostolidi S; Dimopoulos G; Sambatakou H; Valsami G; Meletiadis J; Dokoumetzidis A
    Br J Clin Pharmacol; 2021 Mar; 87(3):1024-1032. PubMed ID: 32633039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.
    Conil JM; Georges B; Ruiz S; Rival T; Seguin T; Cougot P; Fourcade O; Pharmd GH; Saivin S
    Br J Clin Pharmacol; 2011 Jan; 71(1):61-71. PubMed ID: 21143502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: Population pharmacokinetic modelling and simulations for improved dosing schemes.
    Vu DH; Nguyen DA; Delattre IK; Ho TT; Do HG; Pham HN; Dao XC; Tran NT; Nguyen GB; Van Bambeke F; Tulkens PM; Nguyen HA
    Int J Antimicrob Agents; 2019 Dec; 54(6):702-708. PubMed ID: 31600554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients.
    Åsberg A; Bjerre A; Neely M
    Pediatr Transplant; 2014 Feb; 18(1):103-11. PubMed ID: 24152053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics and Dose Optimization of Ganciclovir in Critically Ill Children.
    Li S; Shu C; Wu S; Xu H; Wang Y
    Front Pharmacol; 2020; 11():614164. PubMed ID: 33536921
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimal sparse sampling for estimating ganciclovir/valganciclovir AUC in solid organ transplant patients using NONMEN.
    Padullés Caldés A; Colom H; Caldes A; Cerezo G; Torras J; Grinyó JM; Lloberas N
    Ther Drug Monit; 2014 Jun; 36(3):371-7. PubMed ID: 24305626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
    Fabre MA; Fuseau E; Ficheux H
    J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate.
    de Velde F; de Winter BCM; Neely MN; Yamada WM; Koch BCP; Harbarth S; von Dach E; van Gelder T; Huttner A; Mouton JW;
    Clin Pharmacokinet; 2020 Jul; 59(7):885-898. PubMed ID: 31956969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.